Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases Read more
LianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA Approval of XDEMVY (lotilaner ophthalmic solution) 0.25% for the Treatment of Demodex Blepharitis Read more
Jardiance (empagliflozin) approved in the EU for the treatment of adults with chronic kidney disease Read more
Astellas and PeptiDream Enter into Research Collaboration and License Agreement to Discover Novel Targeted Protein Degraders Read more
ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates Read more
Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million Read more
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk Read more